Cargando…

Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs

The recent identification of human monoclonal antibodies with broad and potent neutralizing activity against HIV-1 (bnAbs) has resulted in substantial efforts to develop these molecules for clinical use in the prevention and treatment of HIV-1 infection. As with any protein therapeutic drug product,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seaman, Michael S., Bilska, Miroslawa, Ghantous, Fadi, Eaton, Amanda, LaBranche, Celia C., Greene, Kelli, Gao, Hongmei, Weiner, Joshua A., Ackerman, Margaret E., Garber, David A., Rosenberg, Yvonne J., Sarzotti-Kelsoe, Marcella, Montefiori, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103754/ https://www.ncbi.nlm.nih.gov/pubmed/31917969 http://dx.doi.org/10.1016/j.jim.2020.112736

Ejemplares similares

To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1
por: Griffith, Sarah A., et al.
Publicado: (2021)

Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques
por: Rosenberg, Yvonne J., et al.
Publicado: (2019)

Understanding the Determinants of BnAb Induction in Acute HCV Infection
por: Underwood, Alexander P., et al.
Publicado: (2018)

Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity
por: Kerwin, Bruce A., et al.
Publicado: (2020)

Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies
por: Bharadwaj, Pranay, et al.
Publicado: (2020)

Predicted broadly neutralizing antibody (bnAb) resistance and associated envelope characteristics of adults with HIV-1 seroconversion in Botswana
por: Moraka, Natasha Onalenna, et al.
Publicado: (2023)

First clinical study of germline-targeting strategy: One step closer to a successful bnAb-based HIV vaccine
por: Sun, Caijun, et al.
Publicado: (2023)

Predicted resistance to broadly neutralizing antibodies (bnAbs) and associated HIV-1 envelope characteristics among seroconverting adults in Botswana
por: Moraka, Natasha O., et al.
Publicado: (2023)

High Temperature SELMA: Evolution of DNA-Supported Oligomannose Clusters Which Are Tightly Recognized by HIV bnAb 2G12
por: Temme, J. Sebastian, et al.
Publicado: (2014)

Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV
por: Brown, Eric P., et al.
Publicado: (2018)

Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design
por: Finney, Joel, et al.
Publicado: (2018)

The Mechanism of bnAb Production and Its Application in Mutable Virus Broad-Spectrum Vaccines: Inspiration from HIV-1 Broad Neutralization Research
por: Zhang, Xinyu, et al.
Publicado: (2023)

Optimization and validation of the HIV-1 neutralizing antibody assay in A3R5 cells
por: Sarzotti-Kelsoe, M, et al.
Publicado: (2012)

P04-39. Recognizing a dynamic HIV-1 target: a structural look at the interaction between bnAb 2F5 and varying gp41 MPER sequences
por: Julien, J, et al.
Publicado: (2009)

International Technology Transfer of a GCLP-Compliant HIV-1 Neutralizing Antibody Assay for Human Clinical Trials
por: Ozaki, Daniel A., et al.
Publicado: (2012)

Short Communication: Potential Risk of Replication-Competent Virus in HIV-1 Env-Pseudotyped Virus Preparations
por: Bilska, Miroslawa, et al.
Publicado: (2017)

Qualification of NISTmAb charge heterogeneity control assays
por: Turner, Abigail, et al.
Publicado: (2018)

Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments
por: Hraber, Peter, et al.
Publicado: (2017)

Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques
por: Rosenberg, Yvonne J., et al.
Publicado: (2016)

Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy
por: Hu, Xintao, et al.
Publicado: (2017)

H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials
por: Sawant, Sheetal, et al.
Publicado: (2023)

Ab initio calculations on structure and stability of BN/CC isosterism in azulene
por: Abdel-Rahman, Mohamed A., et al.
Publicado: (2023)

Validation of an automated system for aliquoting of HIV-1 Env-pseudotyped virus stocks
por: Schultz, Anke, et al.
Publicado: (2018)

Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus
por: Manoharan, Vinoth K., et al.
Publicado: (2018)

Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals
por: Kreer, Christoph, et al.
Publicado: (2023)

Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges
por: Khattar, Sunil K., et al.
Publicado: (2015)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques
por: Pahar, Bapi, et al.
Publicado: (2016)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2014)

An Automated HIV-1 Env-Pseudotyped Virus Production for Global HIV Vaccine Trials
por: Schultz, Anke, et al.
Publicado: (2012)

Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs
por: Hoot, Sam, et al.
Publicado: (2013)

P15-04. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells
por: Todd, CA, et al.
Publicado: (2009)

Multivalent Antigen Presentation Enhances the Immunogenicity of a Synthetic Three-Component HIV-1 V3 Glycopeptide Vaccine
por: Cai, Hui, et al.
Publicado: (2018)

Correction: Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs
por: Hoot, Sam, et al.
Publicado: (2013)

A site of vulnerability at V3 crown defined by HIV-1 bNAb M4008_N1
por: Chan, Kun-Wei, et al.
Publicado: (2021)

Registrable Qualifications
por: Hiranandani, K. M.
Publicado: (1927)

Qualification and Registration
Publicado: (1908)

Medical Qualifications
Publicado: (1905)

Cannot write session to /tmp/vufind_sessions/sess_3la9triss81tksavh1pnhpmusb